These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
12. Combined proteasome and histone deacetylase inhibition: A promising synergy for patients with relapsed/refractory multiple myeloma. Jagannath S; Dimopoulos MA; Lonial S Leuk Res; 2010 Sep; 34(9):1111-8. PubMed ID: 20472288 [TBL] [Abstract][Full Text] [Related]
13. Elotuzumab as a novel anti-myeloma immunotherapy. Radhakrishnan SV; Bhardwaj N; Steinbach M; Weidner J; Luetkens T; Atanackovic D Hum Vaccin Immunother; 2017 Aug; 13(8):1751-1757. PubMed ID: 28604269 [TBL] [Abstract][Full Text] [Related]
14. Elotuzumab for the treatment of multiple myeloma. Wang Y; Sanchez L; Siegel DS; Wang ML J Hematol Oncol; 2016 Jul; 9(1):55. PubMed ID: 27417553 [TBL] [Abstract][Full Text] [Related]
15. Sequential or combination therapy for multiple myeloma. Nooka A; Lonial S Expert Rev Hematol; 2012 Oct; 5(5):533-45. PubMed ID: 23146057 [TBL] [Abstract][Full Text] [Related]
16. Elotuzumab for the treatment of multiple myeloma. Moreau P; Touzeau C Future Oncol; 2014 May; 10(6):949-56. PubMed ID: 24941981 [TBL] [Abstract][Full Text] [Related]
17. Role of carfilzomib in the treatment of multiple myeloma. Khan RZ; Badros A Expert Rev Hematol; 2012 Aug; 5(4):361-72. PubMed ID: 22992230 [TBL] [Abstract][Full Text] [Related]
18. Current and emerging triplet combination therapies for relapsed and refractory multiple myeloma. Pantani L; Brioli A; Tacchetti P; Zannetti BA; Mancuso K; Rocchi S; Martello M; Rizzello I; Terragna C; Zamagni E; Cavo M Expert Rev Hematol; 2016 Mar; 9(3):315-23. PubMed ID: 26634945 [TBL] [Abstract][Full Text] [Related]